COM701
Solid Tumors (e.g., Platinum-Resistant Ovarian Cancer)
Key Facts
Indication
Solid Tumors (e.g., Platinum-Resistant Ovarian Cancer)
Phase
Phase 1/2
Status
Active
Company
About Compugen
Compugen is a computational discovery-driven biotech focused on identifying and developing first-in-class cancer immunotherapies. Its core asset is the proprietary, AI/ML-powered Unigen™ platform, which integrates multi-omics data to predict novel immune checkpoints and therapeutic targets. The company has successfully translated its computational predictions into a clinical pipeline, with multiple programs in Phase 1/2 development. Its strategy is to advance these assets independently or through strategic partnerships to address significant unmet needs in oncology.
View full company profile